注射用纤溶酶合理应用点评标准的建立及应用  

Establishment and application of evaluation standard for rational use of fibrinogenase injection

作　　者：白丽淼 顾平[2] BAI Li-miao;GU Ping(Hebei Energy Xingtai Mining Group General Hospital,Xingtai 054000,China;不详)

机构地区：[1]冀中能源邢矿集团总医院,河北邢台054000 [2]遂宁市中心医院,四川遂宁629000

出　　处：《中国处方药》2021年第9期74-76,共3页Journal of China Prescription Drug

基　　金：邢台市科技计划项目(2019ZC164);遂宁市中心医院科研课题(2019y16)。

摘　　要：目的建立注射用纤溶酶合理应用点评标准,分析该药使用的合理性,以规范和指导临床合理用药。方法以药品说明书为基础,通过文献查阅,建立注射用纤溶酶合理应用点评标准,回顾性分析遂宁市中心医院2019年7月~12月使用注射用纤溶酶的出院病历。结果1480例病例中,平均年龄(63.86±7.28)岁;主要疾病为脑梗死、心肌梗死、动静脉血栓、稳定性心绞痛、突发性耳聋等。用药不合理主要体现在选药不合理277例(18.72%),疗程不合理194例(13.31%),用量不合理21例(1.42%),联合用药不合理23例(1.55%)。结论纤溶酶的应用存在不合理现象,应进行有效干预,促进临床用药水平。点评标准有待进一步完善,以促进纤溶酶的合理使用。Objective To establish the evaluation standard for rational application of fibrinogenase injection,and evaluate clinical use of fibrinogenase injection.Methods Based on the pharmaceutical instruction,evaluation standard for rational application of fibrinogenase injection was established with reference to the related literature.A retrospective analysis method was to rationally evaluate the archived medical records of inpatients who used fibrinogenase injection from July to December of 2019 in Suining Central Hospital.Results The 1480 inpatients,were(63.86±7.28)years old.The main diseases of these inpatients were cerebral infarction,myocardial infarction,arteriovenous thrombosis,stable angina,sudden deafness,etc.The most common types of irrational medication included unreasonable drug selection 277 cases(18.72%),unreasonable treatment 194 cases(13.31%),unreasonable dosage 21 cases(1.42%)and unreasonable combination 23 cases(1.55%).Conclusion The clinical application of fibrinogenase injection in this hospital is unreasonable,and the effective intervention should be carried out to improve the level of clinical rational drug use.The evaluation standard need to be further improved in order to promote the rational use of fibrinogenase injection.

关 键 词：注射用纤溶酶 用药分析 合理用药 

分 类 号：R969.3[医药卫生—药理学]